Connect Biopharma (CNTB) – Investment Analysts’ Weekly Ratings Updates

Connect Biopharma (NASDAQ: CNTB) has recently received a number of price target changes and ratings updates:

• 10/12/2026 – Connect Biopharma is now covered by Leerink Partners. They set an “outperform” rating and a $4.00 price target on the stock.
• 10/8/2026 – Connect Biopharma had its “buy” rating reaffirmed by HC Wainwright.
• 10/2/2026 – Connect Biopharma had its “buy” rating reaffirmed by HC Wainwright.
• 9/30/2026 – Connect Biopharma had its price target lowered by BTIG Research to $5.00. They now have a “buy” rating on the stock.
• 9/24/2026 – Connect Biopharma was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 9/22/2026 – Connect Biopharma had its price target lowered by Oppenheimer Holdings, Inc. to $5.00. They now have an “outperform” rating on the stock.
• 9/16/2026 – Connect Biopharma had its price target lowered by Canaccord Genuity Group Inc. from $7.00 to $6.00. They now have a “buy” rating on the stock.
• 9/15/2026 – Connect Biopharma had its “buy” rating reaffirmed by BTIG Research.
• 9/14/2026 – Connect Biopharma had its “buy” rating reaffirmed by HC Wainwright. They now have a $7.00 price target on the stock.
• 9/3/2026 – Connect Biopharma was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.

Connect Biopharma Corp. is a clinical-stage biopharmaceutical company focused on developing therapies for chronic inflammatory diseases driven by T-cell activity. The company uses its drug-discovery platform to identify and advance small-molecule and antibody-based treatments intended to selectively regulate immune responses while limiting broader immunosuppression.

Its pipeline has included ropsacitinib, formerly known as CBP-307, an oral selective sphingosine-1-phosphate receptor 1 modulator investigated for inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease.